Answers are grounded in this paper and cite their sources.
Messenger RNA (mRNA) therapy offers a programmable route to melanoma treatment, but its translation is limited by nuclease degradation, off-target biodistribution and endolysosomal trapping. Here we report a glutathione (GSH)/pH dual-responsive mRNA nanocomplex (mRNA-NC) fabricated by one-pot in situ polymerization of N-(3-aminopropyl)methacrylamide (APMA), 1-vinylimidazole (VI), N,N′-bis(acryloyl)cystamine (BACA), and 2-methacryloyloxyethyl phosphorylcholine (MPC) on the mRNA template. At an N/P ratio of 40, the carrier reached an encapsulation efficiency of 92.7 ± 2.1% and a loading capacity of 87.4 ± 3.2 μg mg–1, forming monodisperse particles of 126.4 ± 7.2 nm (polydispersity index, PDI, 0.14). The zwitterionic corona limited plasma protein adsorption to 12.6 ± 1.5 μg mg–1 (4.6-fold lower than jetPEI/mRNA), kept hemolysis at 0.8 ± 0.2%, and extended the serum half-life of the mRNA to ≈27.4 h, roughly 9-fold longer than naked mRNA. Release was gated by both triggers: 86.5 ± 3.7% of the cargo was released within 8 h under 10 mM GSH, whereas leakage under physiological conditions remained ≤ 12%; in a 4 h matrix, pH 5.5 plus 10 mM GSH released 85 ± 6.8% versus 12 ± 1.5% at pH 7.4 without GSH. In B16F10 cells, the nanocomplex was taken up in a dose- and energy-dependent manner, entered the lysosomal compartment, and escaped over time in a manner consistent with imidazole-mediated proton-sponge buffering (a hypothesis; intralysosomal pH was not measured directly), producing a peak firefly luciferase (FLuc) expression of 56,140 ± 3280 RLU mg–1 protein at 24 h, about 1.5-fold higher than jetPEI/mRNA, with 93.6 ± 3.9% cell viability and 6.7 ± 1.2% lactate dehydrogenase (LDH) release. In B16F10-bearing albino C57BL/6 mice, a single intravenous dose produced tumor-dominant bioluminescence (peak 5.7 × 106 photons s–1 at 6 h), a tumor enrichment index of 1.22 ± 0.18 (vs 0.31 ± 0.03 for jetPEI/mRNA) and 2.42 × 107 FLuc mRNA copies μg–1 tumor RNA at 12 h, while all 7-day safety indicators remained at phosphate-buffered saline (PBS) levels. These results demonstrate that a single zwitterionic nanocomplex can integrate stealth, dual-triggered release, and endosomal escape for safe, tumor-enriched mRNA delivery. While this study focuses on delivery performance and reporter gene expression, it lays a solid foundation for future therapeutic applications with functional mRNA.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: